Trial Profile

A phase II clinical trial of EGF1-48

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epidermal growth factor-1-48 (Primary)
Indications Guillain-Barre syndrome; Optic neuritis; Polyneuropathy
Focus Therapeutic Use
Sponsors biOasis Technologies

Most Recent Events

20 Jun 2022 New trial record
16 Jun 2022 According to a biOasis Technologies media release, the members of the Cresence team have entered into consultancy agreements with Bioasis and will be involved in preparations for the Phase 2 clinical trials of EGF1-48.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com